). Neonates whose mothers had у10 mg/mL P p .01 IgG anti-GBS type III had a 91% lower risk for EOD, compared with those whose mothers had levels of !2 mg/mL. A vaccine that induces IgG anti-GBS type III levels of у10 mg/mL in mothers can be predicted to offer a significant degree of protection against EOD caused by this pathogen.
Group B streptococcus (GBS) is the leading cause of sepsis, pneumonia, and meningitis in neonates and infants in the first 3 months after birth [1] . GBS type III accounts for ∼25% of early-onset disease (EOD) and ∼90% of late-onset disease (LOD) caused by this pathogen [2, 3] . Because of the prevalence of maternal GBS carriage and the severity of the disease in neonates, national guidelines for the prevention of GBS disease, based on intrapartum antibiotic prophylaxis, were pub-lished in 1996 [1] . The widespread use of intrapartum antibiotic prophylaxis has reduced early-onset GBS disease, but the incidence of LOD has remained unchanged [4] . Investigators suggest that intrapartum antibiotic prophylaxis will not prevent LOD [1] .
The protective activities of human IgG GBS type-specific antibody have been demonstrated by in vitro and in vivo assays. A correlation between susceptibility to early-onset GBS disease and low levels of maternal GBS polysaccharide type-specific antibody has been established [5] [6] [7] [8] [9] [10] [11] . A seroepidemiological study showed that the probability of developing early-onset GBS type Ia disease decreased with increasing levels of maternal IgG against GBS type Ia [12] .
Active immunization of neonates cannot provide protection against EOD, because ∼90% of cases occur within 24 h after birth. A polysaccharide-based vaccine given to mothers to induce passive maternal-fetal transfer of IgG GBS type-specific antibodies has been developed and has undergone clinical evaluations [6, 7, [13] [14] [15] [16] [17] [18] . Because of the difficulty of conducting efficacy trials for GBS, licensure may have to rely on studies that measure vaccine-induced antibody levels that correlate with protection [19, 20] .
We undertook a multicenter seroepidemiological study from July 1995 to June 1999 to estimate protective levels of maternal antibody against neonatal EOD and have reported our findings for IgG anti-GBS type Ia [12] . The present report describes the level of maternal IgG GBS type-specific antibody required to protect neonates against early-onset GBS disease caused by GBS type III.
PATIENTS, MATERIALS, AND METHODS
A case-control design was used to evaluate the relationship between levels of IgG anti-GBS type III in maternal and cord serum and the occurrence of EOD, as described elsewhere [12] . Levels of IgG GBS type-specific antibody in maternal and cord serum samples from neonates with EOD (case patients) were compared with those from neonates colonized by GBS type III at birth who did not develop GBS disease (control subjects). For analysis of protective maternal-serum antibody levels, we included only neonates born at у34 weeks gestation, because transplacental transfer of IgG is not efficient before then [12] . Analysis of protective cord-serum antibody levels included neonates of all gestational ages. For each case patient, up to 4 lightly and 4 heavily colonized neonates born at the same hospital within 6 months of the case patient were selected as control subjects.
Blood and cerebrospinal fluid (CSF) isolates were identified as GBS by routine methods; cultures from the throat, anus, umbilicus, and ears were obtained as described elsewhere [12] . All b-hemolytic colonies and suspicious nonhemolytic colonies were tested for GBS by latex agglutination (Patho Dx; Diagnostic Products). The capsular type of each isolate was determined by an inhibition ELISA for GBS types Ia, Ib, II, III, and V [21] .
Maternal and cord serum samples were assayed by ELISA for IgG anti-GBS type III, as described elsewhere [22] . In accordance with the antigen-coating optimization method described elsewhere [23] , GBS type III polysaccharide (2 mg/mL) mixed with 0.5 mg/mL methylated human serum albumin was coated onto microplates (Immulon 4; Dynatech Laboratories). The native GBS type III polysaccharide was purified by the method of Carey et al. [24] . In brief, from concentrated culture supernatant containing both free GBS type III polysaccharide and polysaccharide bound to group B antigen, we isolated group B antigen-free type III polysaccharide by gel filtration and ion-exchange chromatography. The coated plates were left overnight at room temperature and were washed with PBS containing 0.05% Tween 20. A reference serum sample (serum 19) , containing an assigned value of 143 mg/mL IgG anti-GBS type III (as determined by immunoprecipitation) [25] , was provided by Lisa Basham (Nabi Biopharmaceuticals; Rockville, MD). Serum 19 was from an adult vaccinated with a 4-valent GBS polysaccharide vaccine that included GBS type III. The serum samples were diluted in PBS containing 0.1% Brij 35, 5% newborn calf serum, and 0.05% sodium azide. Triplicate 2-fold dilutions of human serum samples or the reference serum sample were added to the control plates and incubated overnight at 4ЊC. A single predetermined dilution of each of 3 quality-control serum samples was included on each plate. After the wells were further washed, an optimal dilution of goat antihuman IgG conjugated to alkaline phosphatase (Sigma) was added and incubated for 2 h at room temperature. Color was developed by the addition of 1 mg/mL p-nitrophenyl phosphate (Sigma 104) in 1.0 mol/L Tris buffer with 0.3 mmol/L MgCl 2 (pH 9.8) within 20-30 min. Absorbance was measured (at an optical density of 405 nm) by use of a Bio-Tek 900C microtiter reader. Antibody values were calculated by use of a weighted loglogit ELISA program [23] . On the basis of an analysis of 117 quality-control replicates for each of the 3 quality-control serum samples, the assay-to-assay coefficient of variation was ∼15%.
The protective level of antibody was estimated by IgG anti-GBS type III levels associated with a significant reduction in risk for EOD ( ), as described elsewhere [12] . Trend analysis P ! .05 for antibody levels and risk for EOD was performed by logistic regression with continuous log-antibody term [26] . The efficiency of maternal-fetal transfer of antibodies was calculated as (cord geometric mean [GM] antibody level/maternal GM antibody level) ϫ 100 [27] .
RESULTS
Case patients and control subjects. EOD was diagnosed by isolation of GBS from the blood or CSF within 7 days of birth. Daily surveillance of newborn nurseries and microbiology laboratories of 14 participating hospitals in 6 academic centers identified 132 EOD cases [12] . (The present study was approved by the institutional review board of each study center.) Twentynine case patients (22%) were infected with GBS type III, including 1 in whom GBS types Ia and III were both isolated from the blood. These 29 case patients were from Alabama (6), California (9), Florida (3), New York City (2), and Texas (9). GBS was isolated from the blood of 25 case patients and from both the blood and the CSF of 4 case patients. Twenty-five case patients (86%) had onset of symptoms or signs within 24 h of birth. All but 1 case patient survived. Maternal and/or cord serum samples were available from 29 case patients and included 26 paired maternal and cord serum samples, 2 maternal serum samples, and 1 cord serum sample.
Cultures from the throat, anus, umbilicus, and ears were obtained from 17,690 neonates, of whom 1654 (9%) were colonized with GBS but did not develop disease [12] . Of the colonized neonates, 330 (20%) had GBS type III identified from surface culture: of them, 97 (29%) were heavily colonized (positive at 3 or 4 anatomic sites) and 233 (71%) were lightly colonized (pos- Figure 1 shows the distribution of levels of maternal IgG anti-GBS type III for 26 case patients and 143 matched control subjects born at у34 weeks gestation. Eleven case patients (41%), compared with 27 control subjects (19%), had maternal IgG anti-GBS type III levels of !2 mg/mL ( ). One case P p .008 patient, born at 38 weeks gestation, had a maternal level of 10.4 mg/mL and a cord level of 4.8 mg/mL. No case patients had maternal levels of 110.4 mg/mL, whereas 26 control subjects (18%) had levels higher than this value. Figure 1 . Distribution of maternal and cord serum levels of IgG anti-group B streptococcus (GBS) type III, in neonates with early-onset disease (EOD) caused by GBS type III (case patients) and neonates who were colonized by GBS type III but did not develop EOD (control subjects).
Estimation of protective level of IgG anti-GBS type III in maternal serum (table 2).
Maternal serum samples for 26 case patients and 143 control subjects born at у34 weeks gestation were analyzed to estimate the protective type-specific antibody levels. Because the number of case patients and control subjects with maternal antibody levels of !1 mg/mL was small (2 case patients and 3 control subjects), we used a maternal antibody level of !2 mg/mL as the reference (i.e., odds ratio [OR] p 1). The OR for EOD was adjusted for female sex of neonate; maternal fever, performance of invasive procedures, and receipt of antibiotics during labor; and delivery by Cesarean section. The adjusted OR was 0.25 (95% confidence interval [CI], 0.10-0.67) for mothers with levels of у2.0 mg/mL. The OR decreased thereafter with increasing levels of maternal antibody-from 0.23 (95% CI, 0.07-0.78) for mothers with levels of у5.0 mg/mL, to 0.22 (95% CI, 0.05-0.93) for mothers with levels of у8.0 mg/ mL, and to 0.09 (95% CI, 0.01-0.78) for mothers with levels of у10 mg/mL. Correspondingly, the percent reduction of the risk for delivering a neonate with EOD increased from 75% for mothers with levels of у2 mg/mL, to 77% for mothers with levels of у5 mg/mL, to 78% for mothers with levels of у8 mg/mL, and to 91% for mothers with levels of у10 mg/mL. A trend analysis showed that the probability of EOD occurrence decreased with increasing maternal antibody levels ( ). P p .01
Placental transfer of IgG anti-GBS type III (table 3).
Twenty-six case patients and 298 colonized neonates of all ges- , for the difference in percentage of placental transfer between these 2 gestational age P p .18 groups (comparison of the ratio of GM levels for the cord and maternal serum samples of the 2 gestational age groups, with a large sample variance obtained by the method of statistical differentials).
tational ages with paired maternal and cord serum samples were analyzed for placental transfer of IgG anti-GBS type III. The efficiency of placental transfer of IgG anti-GBS type III was 71% in case patients and 76% in colonized neonates ( ). In neonates born at !34 weeks gestation ( ), P 1 .05 n p 5 the cord level was 56% of the maternal level, compared with 76% in neonates born at у34 weeks gestation ( ) n p 319 ( ). The transfer was 66% in neonates born at 34-36 P p .18 weeks gestation ( ) and 77% in neonates born at у37 n p 21 weeks gestation ( ). n p 298 IgG anti-GBS type III in cord serum. Cord serum samples were available for assaying from 27 case patients and 312 colonized neonates of all gestational ages. The GM level of IgG anti-GBS type III in cord serum was significantly lower in case patients, compared with that in colonized neonates (2.03 vs. 3.29 mg/mL [ ]). The analysis of the protective levels P p .002 of IgG anti-GBS type III in cord serum against EOD included 27 case patients and 156 matched control subjects of all gestational ages. Figure 1 shows the distribution of levels of IgG anti-GBS type III in the cord serum samples for these case patients and control subjects.
With a cord serum IgG anti-GBS type III level of !2 mg/mL as the reference in multivariate analysis, the adjusted OR for EOD was 0.31 (95% CI, 0.13-0.73) in neonates with levels of у2 mg/mL, 0.26 (95% CI, 0.08-0.91) in neonates with levels of у5 mg/mL, and 0.15 (95% CI, 0.03-0.71) in neonates with levels of у6 mg/mL. At cord serum levels of у6 mg/mL, there was an 85% reduction in risk for EOD caused by GBS type III. No case patient had an IgG anti-GBS type III level of у7 mg/mL in cord serum, whereas 35 control subjects (22%) did ( ). The P p .006 probability of EOD decreased significantly with increasing levels of IgG anti-GBS type III in cord serum ( ). P p .01
DISCUSSION
We have shown that the risk for EOD caused by GBS type III is inversely related to levels of maternal IgG anti-GBS type III. There was a 75% lower risk for EOD in neonates of у34 weeks gestation born to mothers with a serum IgG anti-GBS type III level of у2 mg/mL, compared with that for neonates of у34 weeks gestation born to mothers with an antibody level of !2 mg/mL. The magnitude of the reduction of risk increased with increasing levels of antibody and reached 91% in mothers with antibody levels of у10 mg/mL. We have estimated that neonates whose mothers had IgG anti-GBS type Ia levels of у5 mg/mL had an 88% lower risk for developing EOD caused by GBS type Ia [12] .
We have confirmed that suboptimal placental transfer of IgG anti-GBS type III occurs in neonates born at !34 weeks gestation and that efficiency of transfer increases with gestational age: 66% of maternal level in neonates born at 34-36 weeks gestation and 77% in those born at у37 weeks gestation. This observation is similar to that in a report by Baker et al. [6] and to our estimate of placental transfer of naturally acquired IgG anti-GBS type Ia [12] . Our estimates showed that IgG anti-GBS type III levels of у6 mg/mL in cord serum were associated with an 85% reduction in the risk for EOD. We found that no case patients had cord serum levels of у7 mg/mL, whereas 22% of control subjects did, implying that this is a protective level. After the variation in efficiency of maternal-fetal transfer of IgG anti-GBS type III (i.e., 56% in neonates born at !34 weeks gestation, 66% in neonates born at 34-36 weeks gestation, and 77% in neonates born at у37 weeks gestation) is accounted for, the corresponding maternal protective levels are estimated to be 12.5 mg/mL for neonates born at !34 weeks gestation, 10.6 mg/mL for neonates born at 34-36 weeks gestation, and 9.1 mg/mL for neonates born at у37 weeks gestation.
The protective levels of antibody seem to vary with the pathogen. For example, the estimated protective level is 0.15 mg/ mL for invasive Hemophilus influezae type b disease [28] , 0.2 mg/mL for invasive pneumococcal disease [29] , 2 mg/mL for group A meningococcal meningitis and septicemia [30] , and 4 mg/mL (cord serum) for GBS type Ia [12] . We have estimated the protective level of maternal IgG anti-GBS type III to be у10 mg/mL. This level has been achieved with GBS type IIItetanus toxoid conjugate, if we are to judge by the vaccineinduced GM IgG anti-GBS type III level that was measured by ELISA using GBS type III-human serum albumin conjugate as the coating antigen [18] . A 12.5-mg dose of this conjugate induced a GM level of IgG anti-GBS type III of 15.8 mg/mL 4 weeks after vaccination [18] . The percentage of vaccinees with levels of 110 mg/mL was, however, not reported.
Studies have shown that adults with low levels of preimmunization antibody respond suboptimally to either native GBS type III polysaccharide or protein conjugate vaccines [7, 31] .
Although reimmunization of low responders with GBS type III protein conjugate vaccines boosted their response, the GM level of antibody was still less than one-half of that achieved by high responders [28] . We have shown in the present study that 22% of mothers of GBS type III-colonized neonates had IgG anti-GBS type III levels of !2 mg/mL. These mothers may respond inadequately to GBS vaccines.
In conclusion, newborn neonates whose mothers have IgG anti-GBS type III serum levels of у10 mg/mL have a 91% reduced risk for EOD, and, when cord serum levels were у7 mg/mL, no neonates had EOD caused by this pathogen. Thus, the efficacy of vaccination can be estimated by the percentage of women or their newborn neonates who achieve these protective antibody levels after immunization.
